
Simoa® IL-12 p70 Advantage Kit HD-1/HD-X Data Sheet

Description


Interleukin-12, p70 (IL-12 p70) is a disulfide-linked heterodimeric 70-kDa cytokine composed of a 197 amino acid 35-kDA (p35) subunit and a 306 amino acid 40-kDa (p40) subunit. It is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells in response to antigenic stimulation. IL-12 stimulates growth and function of T cells, production of interferon-gamma (IFN- γ) and tumor necrosis factor-alpha (TNF- α) from T cells and natural killer (NK) cells, and reduces IL-4mediated suppression of IFN-y. IL-12 has been reported to be associated with autoimmune and inflammatory conditions. Increased IL-12 plasma levels may also be detected in patients with neurological disorders such as multiple sclerosis.

Calibration Curve: Four-parameter curve fit parameters are depicted.



Limit of Detection (LOD): Calculated as 2.5 standard deviations from the mean of background signal read back on each calibration curve over 10 runs.


Sample Dose CV Profile: Triplicate measurements of diluted serum samples assayed over multiple runs (45 measurements. LLOQ determined as the concentration at which %CV exceeds 20% according to the power equation fit to the data.



| LLOQ | 0.0170 pg/mL |
|----------------------------------|-----------------------------------------|
| LOD | 0.0048 pg/mL SD 0.00332 pg/mL |
| Dynamic range (serum and plasma) | 0–40 pg/mL |
| Diluted Sample volume* | 100 μL per measurement |
| Tests per kit | 96 |

^{*}See Kit Instruction for details

Endogenous Sample Reading: Healthy donor matched EDTA plasma (n=20) and serum (n=20) were measured. Error bars depict median with interquartile range.





Simoa® IL-12 p70 Advantage Kit HD-1/HD-X Data Sheet Item 100988

| Sample Type | Median IL-12 p70 pg/mL | % Above LOD |
|-------------|---------------------------|-------------|
| Serum | 0.205 | 100% |
| Plasma | 0.193 | 100% |

Precision: Five samples consisting of one plasma panel, two serum panels, and two IL-12 p70 controls were assayed in replicates of three at two separate times per day for five days using a single lot of reagents and calibrators. Analysis of variance (fully nested ANOVA) results are summarized in the following table.

| Sample | Mean (pg/mL) | Within run CV | Between run CV | Between day CV |
|-----------|-----------------|------------------|-------------------|-------------------|
| Control 1 | 0.0947 | 7.4% | 0.0% | 8.4% |
| Control 2 | 8.19 | 5.3% | 12.5% | 0.0% |
| Panel 1* | 0.126 | 7.1% | 9.5% | 0.0% |
| Panel 2 | 0.299 | 10.0% | 5.0% | 0.0% |
| Panel 3 | 22.2 | 5.9% | 13.3% | 0.0% |

^{*}Plasma

Spike and Recovery: IL-12 p70 spiked into 4 serum samples at 5 and 20 pg/mL.

Admixture Linearity: Spiked serum sample admixed with low IL-12 p70 sample, mean of 10 levels.

Dilution Linearity (Serum): Spiked serum was diluted 2x serially from MRD (4x) to 1,024x with Sample Diluent.

Dilution Linearity (Plasma): Spiked EDTA plasma was diluted 2x serially from MRD (4x) to 1,024x with Sample Diluent.

| Spike and Recovery (Serum) | Mean = 77.1% Range: 70.2–81.8% |
|----------------------------|------------------------------------------|
| Admixture Linearity | Mean = 95.1% Range: 80.4–105% |
| Dilution Linearity | Mean = 114.7% |
| (Serum – 1,024x) | Range: 108.4–122.7% |
| Dilution Linearity | Mean = 86.5% |
| (Plasma – 1,024x) | Range: 56.1–114% |